PUBLIC COMPANY
saveGLAND
USupdated 3mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Lilly adds to immune drug pipeline with $2.9B Merida buyoutThe big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.biopharma_dive · 19d ago
- Scientists deploy Merck’s Ebola vaccine in DRCProstate cancer therapy, Meta glasses in hospital settings, and more health news from Morning Roundsstat · 29d ago
- Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation.stat · 29d ago
- MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get themPre-biopsy MRI is standard outside the U.S., but the latest data show such scans were done in only about a third of U.S. prostate cancer cases in 2022.stat · 1mo ago
- BridgeBio gets funding for drug launch; United buys into cell therapyElsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.biopharma_dive · 2mo ago
- Ethyreal starts up with $101M and takes aim at a pair of immune diseasesThe startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.biopharma_dive · 3mo ago
comments(0)
5-min edit window · permanent after that